Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

40.0%

2 terminated/withdrawn out of 5 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1
4(80.0%)
Phase 2
1(20.0%)
5Total
Phase 1(4)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT04270149Phase 1Active Not Recruiting

Cancer Peptides Plus GM-CSF and Adjuvant in Breast Cancer

Role: lead

NCT03832855Phase 1Active Not Recruiting

Assessing the Immunogenicity of pING-hHER3FL

Role: lead

NCT03632941Phase 2Active Not Recruiting

A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast Cancer

Role: lead

NCT03333031Phase 1Terminated

A Study of HS-196, an HSP90 Inhibitor-linked NIR Probe for Solid Malignancies

Role: lead

NCT03906643Phase 1Withdrawn

HS-201, an HSP90 Inhibitor-linked Verteporfin for Detection of Solid Malignancies

Role: lead

All 5 trials loaded